US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections. "This is a historic day in the decades-long fight against HIV," Gilead chairman and chief executive Daniel O'Day said in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine. The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada.
In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada. Reported side effects included injection site reactions, headache, and nausea. Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year."
Price concerns dampen hope
Despite the impressive results, optimism may be tempered by the drug's cost -- a list price of $28,218 per year in the United States, Gilead spokeswoman Blair Baumwell told AFP in an email Wednesday.
An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.
Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually.
Baumwell said the $28,000-plus per year cost for Lenacapavir as a preventive drug is "in line with" those of existing PrEP products and that the company inspects insurers to cover it.
"We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage," she said in the email. Activists are urging Gilead to drastically cut the price to help end the HIV pandemic.
"Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year.
"I congratulate Gilead and US partners for advancing this important innovation," added Winnie Byanyima, under-secretary-general of the United Nations. "Lenacapavir could be the tool we need to bring new infections under control -- but only if it is priced affordably and made available to everyone who could benefit."
In October, Gilead signed agreements with six pharmaceutical companies to produce and distribute generic versions of the drug, pending regulatory approval, in 120 low- and middle-income countries.
Because it will take time for those countries to begin production, the company also announced a separate deal in December with the Global Fund -- an international partnership established by the United Nations, alongside the US President's Emergency Plan for AIDS Relief (PEPFAR) and others -- to purchase doses for two million people.
However, cuts to the PEPFAR program under President Donald Trump's administration have cast uncertainty over the future of that agreement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
4 hours ago
- New Indian Express
Rosemary and a breakthrough blood test: The Alzheimer's research that has Bill Gates excited
Microsoft founder and US billionaire Bill Gates recently shared a post on his X handle about a new blood test for Alzheimer's that was approved by the US Food and Drug Administration (FDA) last month, along with other promising advancements in Alzheimer's research. Gates, who has a personal and emotional connection to the disease—his father, William Gates, passed away in 2020 after a long battle with Alzheimer's—said he is genuinely excited about the progress being made in prevention, early diagnosis, and effective treatment. Bill Gates, who wrote about the first blood test approved by FDA to diagnose Alzheimer's, said that; "...breakthroughs like this will make earlier, easier diagnosis possible—bringing us closer to better treatments and, someday, a cure." As reported by The New Indian Express (TNIE Online) last moth the FDA approved the world's first blood test that helps detection of Alzheimer's disease in May. Among the latest breakthroughs aimed at treatment of this yet incurable disease, another emerging name is Rosmarinus officinalis also known as Rosemary herbs -- an aromatic evergreen herb native to the Mediterranean region.
News18
5 hours ago
- News18
What Is Aspergillus Fumigatus? All About The Deadly Fungus Spreading In US
Last Updated: A dangerous fungus called Aspergillus fumigatus is rapidly spreading throughout the United States. A dangerous fungus is making headlines in the US for its alarming ability to invade the human body and destroy tissue from within. Identified as Aspergillus fumigatus, this fast-spreading pathogen has scientists concerned, especially as warmer temperatures could accelerate its growth. What Is This Deadly Fungus And How Can You Stay Safe From It? Here's What You Need To Know Aspergillus fumigatus is a fungus that spreads through the air, releasing microscopic spores known as conidia. These spores are so small that people often inhale them unknowingly. Common in the environment, this fungus can be found in soil, decaying plants, and even household dust. The National Library of Medicine notes that it grows best at around 37°C and can thrive in warm, moist settings. Remarkably, it can even survive in compost piles at temperatures exceeding 120°F for extended periods. While most individuals' immune systems can fight off the spores without issue, some people, especially those with weakened immunity, can develop a severe lung condition known as aspergillosis. In extreme cases, this infection can progress to organ failure and become fatal. Who Could Become Infected? Reportedly, those most vulnerable to infection include individuals with weakened immune systems. This includes people undergoing cancer treatment, those with asthma or HIV, individuals with low white blood cell counts, and those recovering from recent illnesses like the flu. Health officials note that tracking the fungus is challenging, as aspergillosis is not a reportable disease – its cases, hospitalisations and deaths aren't officially recorded. Around 40,000 cases progress into chronic pulmonary aspergillosis, a long-lasting lung infection. Though invasive aspergillosis is rare, it poses a greater threat by spreading from the lungs to organs like the brain, heart and kidneys. How To Stay Safe From Aspergillus Fumigatus Infection To reduce the risk of infection, doctors are said to have recommended that people with weakened immune systems steer clear of soil, gardening, and environments with mould. It's also advised to wear masks in dusty places and ensure clean, filtered air, especially in hospitals and at home. In response, hospitals in affected states have already started conducting mould inspections and implementing antifungal safety protocols.
NDTV
5 hours ago
- NDTV
Revolutionary New Drug Offers 99.9% Protection Against HIV
Despite decades of progress in HIV treatment, more than a million people are newly infected each year, and an effective vaccine remains out of reach. In a breakthrough, the US Food and Drug Administration has approved lenacapavir, a long-acting drug that offers near-complete protection against HIV with just two injections annually. While HIV prevention drugs, known as pre-exposure prophylaxis (PrEP), have existed for over a decade, their global impact has been limited due to the need for daily pill intake, a routine many struggle to follow consistently. "This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention. Gilead scientists have made it their life's work to end HIV, and now, with the FDA approval of Yeztugo and in collaboration with our many partners, we can help to make that goal a reality." In 2024, Science hailed lenacapavir as its "Breakthrough of the Year". Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents making it functionally akin to a powerful vaccine. The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada. In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada. Reported side effects included injection site reactions, headache, and nausea. Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year." Pricing Raises Concerns Over Accessibility Despite the impressive results, optimism may be tempered by the drug's expected high cost. An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact. While Gilead hasn't disclosed a price for Yeztugo, analysts estimate the US launch cost could reach $25,000 per year. Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually, though that is expected to drop when used as a preventive. Activists are urging Gilead to drastically cut the price to help end the HIV pandemic. "Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year. "To charge one thousand times more for a medicine with pandemic-ending potential would be abhorrent," added Winnie Byanyima, under-secretary-general of the United Nations. "We cannot end AIDS with medicines that are so costly." The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both abroad and within the United States.
